Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte Names Kevin Haas as Chief Development and Technology Officer
04:15pm, Monday, 16'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.
Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT
04:23am, Monday, 16'th Mar 2026
Bamco Inc. NY lowered its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange
Artisan Partners Limited Partnership Acquires 1,048,692 Shares of Veracyte, Inc. $VCYT
03:26am, Friday, 27'th Feb 2026
Artisan Partners Limited Partnership raised its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 16.6% during the third quarter, according to its most recent filing with the Securities and Excha
Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises
12:25pm, Thursday, 26'th Feb 2026
VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.
Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells
07:30am, Thursday, 26'th Feb 2026
The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
10:17pm, Wednesday, 25'th Feb 2026
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates
09:06pm, Wednesday, 25'th Feb 2026
Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago.
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Wednesday, 25'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
09:00am, Tuesday, 24'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCOGU--Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium.
Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy?
10:46am, Monday, 23'rd Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Granite Investment Partners LLC Has $16.38 Million Stock Position in Veracyte, Inc. $VCYT
04:04am, Monday, 23'rd Feb 2026
Granite Investment Partners LLC reduced its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 25.0% in the undefined quarter, according to its most recent filing with the Securities and Exchange
Veracyte to Participate in Upcoming Investor Conferences
05:00pm, Thursday, 19'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond Ja
Illinois Municipal Retirement Fund Takes Position in Veracyte, Inc. $VCYT
04:03am, Wednesday, 18'th Feb 2026
Illinois Municipal Retirement Fund acquired a new position in shares of Veracyte, Inc. (NASDAQ: VCYT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings
09:56am, Monday, 16'th Feb 2026
VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year over year.
Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Thursday, 05'th Feb 2026
The heavy selling pressure might have exhausted for Veracyte (VCYT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
